Cancer cells can break down the protective covers around nerves, causing nerve injury that triggers chronic inflammation leading to immune exhaustion and eventual resistance to immunotherapy, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.
